Please login to the form below

Not currently logged in
Email:
Password:

Relovair

This page shows the latest Relovair news and features for those working in and with pharma, biotech and healthcare.

Breathing easier

While there are several therapies currently in late-stage clinical trials for COPD — including aclidinium bromide (Eklira, Almirall Prodesfarma/Forest Laboratories), vilanterol/fluticasone furoate (Relovair, GSK), andolast (Rottapharm Madaus) and

Latest news

  • GSK increases Theravance investment

    The centrepiece of the partnership is a phase III product for asthma called Relovair (fluticasone furoate/vilanterol trifenatate), which is a potential once-daily therapy combining a long-acting beta2 agonist

  • Phase III trials begin for Relovair

    The first asthma patient has commenced treatment with GlaxoSmithKline's Relovair in a phase III programme. ... The first asthma patient has commenced treatment with GlaxoSmithKline's (GSK) Relovair in a phase III programme.

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Interview: Deepak Khanna, ABPI Interview: Deepak Khanna, ABPI

    Referencing a 'real-world' study into GlaxoSmithKline's (GSK) Relovair in Salford, he says: “We have a good example where the NHS partnered with three companies to focus on COPD.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....